The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
about
Deep Response in Multiple Myeloma: A Critical ReviewThalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Bortezomib: the evidence of its clinical impact in multiple myeloma.PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.Molecular monitoring of minimal residual disease in patients with multiple myeloma.Evolving treatment strategies for myeloma.Future directions in multiple myeloma treatment.Cure of multiple myeloma -- more hype, less reality.High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.In pursuit of the allo-immune response in multiple myeloma: where do we go from here?Guidelines for the diagnosis and management of multiple myeloma 2011.Managing multiple myeloma in the elderly: are we making progress?Sequential or combination therapy for multiple myeloma.Association of response endpoints with survival outcomes in multiple myeloma.Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.Transplantation for Multiple Myeloma.Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma.Detection of minimal residual disease by flow cytometry for patients with multiple myeloma submitted to autologous hematopoietic stem cell transplantation.Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.Predicting durable remissions following thalidomide therapy for relapsed myeloma.Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.Detection of tumour cells in the bloodstream of patients with uveal melanoma: influence of surgical manipulation on the dissemination of tumour cells in the bloodstream.Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers.Guidelines on the diagnosis and management of multiple myeloma 2005.A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myelomaThe Pavia Approach to Clinical Protein AnalysisThe use of fluorescent molecular beacons in real time PCR of IgH gene rearrangements for quantitative evaluation of multiple myeloma
P2860
Q26771228-47A63248-9A68-4C86-99E3-F5989826DBB6Q33364235-F8C99BBD-338B-43B1-AD99-A6387EF93379Q33400724-69C2209A-CDA9-4433-B336-E54D3719F97CQ34426066-17FD4D3A-B5E8-4726-9CC2-6CC3A2E10589Q35668677-C3607F99-E969-447F-A131-FF25368CB15FQ36012354-D8C90C46-5295-445D-8650-1E28F0507105Q36258701-61C1C732-5B4C-4281-9F04-D28E049604B4Q36301128-D5FFEB9F-220C-4555-B4D8-E09EC3AA0810Q36407446-F4D850D4-0889-4569-A156-2F815632776CQ36969778-B1B7D270-F597-43C2-B8E5-E49F43B76EC9Q37349835-8E8FB7A2-819D-4886-B954-54AADF7FD4DDQ37875193-780F6F9A-7C3C-42D5-908B-7A4ED3681510Q37888716-B67BF071-571A-470C-BE33-1BA49A144ADAQ38059253-693500E9-B598-42C8-A4D6-A64386AF7270Q38122624-1FAF4917-DCD9-444F-9648-6A77B0805072Q38249930-14C03C69-FA92-4C08-87ED-0A234035E223Q38256196-50938C72-EDC0-474A-AA91-F1F5560D9369Q38970603-04BFB9A7-3E49-4104-9698-A2EA8F82312BQ39386287-F0EDC5E7-B7EE-4749-8CB3-216C74325001Q40368431-3AD6A06F-6ABD-4090-AB8E-CE039C1D50E6Q40469944-23EDEE75-79EC-4BD9-9DD9-939B7B2C2365Q42191002-F4E0B555-E6BF-4BE1-91AA-806968F7ECE0Q43100815-E4A884AC-7EB0-42FE-8A4A-4EBD4281FB88Q43433333-0750E27F-2E94-4B8F-8927-0967239F566EQ44004543-55A1E6EE-080D-40D1-8230-A2A4F1C1416FQ44267559-1677FBB5-8FBA-444D-8777-45EBAF0A5CC9Q44558771-433A0F1D-F9B8-4DD3-B9E7-3987CE62FFD2Q44763325-2D049298-CD55-437D-9630-99366FD890DAQ45287020-2884FB77-7967-4671-9497-3E37E80AEB25Q46509821-128A0737-55CC-4A07-8D08-4E0D2AD9B21FQ46648237-5E594621-49B4-4B8A-AFD5-60E625FA34D5Q46772655-3CEC0A6D-C24B-4BA9-B51E-D27467D4560EQ47996009-28E028F3-E5A0-45DE-B1B1-77FB175143B7Q52863098-9FA5B74F-5FF7-43C0-AF89-218397694F4FQ52948043-38813A00-FFBC-4576-A691-B5C43F65B201Q53556535-2AB1D127-4809-4A4F-96C5-2FF1B45D3AF4Q56461696-D61CCB7D-9558-41DE-A611-BF349BAA0E2CQ58030636-3E784B95-98F5-4E74-94E3-7B6500FC0B88Q58039991-5BFA8523-62D3-4A0D-8B7E-59E0B935B993
P2860
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The impact of attaining a mini ...... antation for multiple myeloma.
@en
The impact of attaining a mini ...... antation for multiple myeloma.
@en-gb
The impact of attaining a mini ...... antation for multiple myeloma.
@nl
type
label
The impact of attaining a mini ...... antation for multiple myeloma.
@en
The impact of attaining a mini ...... antation for multiple myeloma.
@en-gb
The impact of attaining a mini ...... antation for multiple myeloma.
@nl
prefLabel
The impact of attaining a mini ...... antation for multiple myeloma.
@en
The impact of attaining a mini ...... antation for multiple myeloma.
@en-gb
The impact of attaining a mini ...... antation for multiple myeloma.
@nl
P2093
P2860
P1476
The impact of attaining a mini ...... antation for multiple myeloma.
@en
P2093
Forsyth PD
Richards SJ
P2860
P304
P356
10.1046/J.1365-2141.2001.02530.X
P407
P577
2001-03-01T00:00:00Z